Delays in NSTEMI Hospitalization Linked to Lower Survival

Ted Bosworth

January 24, 2022

Patients who do not receive care for non–ST-segment elevation myocardial infarction (NSTEMI) within 24 hours have a substantially increased risk of mortality 3 years later when compared with those receiving earlier intervention, according to a population-based study evaluating more than 6,000 patients.

The characteristics of patients receiving NSTEMI care more than 24 hours after symptom onset were different from those treated earlier, but understanding these differences might provide clues for improved pathways to care, according to the investigators of this study, published in the Journal of the American College of Cardiology.

In a study of 6,544 NSTEMI patients in the Korea Acute Myocardial Infarction Registry, 1,827 (27%) were evaluated and treated 24 hours or more after symptom onset. When compared with the group with a shorter symptom-to-door time, outcomes at a median follow-up of 1,098 days were substantially worse.

Most importantly, this included a more than 50% absolute unadjusted increase in death from any cause (17.0% vs. 10.5%). On a 3-year adjusted multivariate hazard ratio, the increase was 35% (HR, 1.35; 95% confidence interval, 1.17-1.56; P < .001)

The absolute relative increase in cardiac death was similar in the delayed treatment group (10.8% vs. 6.4%) with a 37% increase in the 3-year multivariate adjustment (HR, 1.37; 95% CI 1.14-1.65; P < .001).

Delay Raises Composite Adverse Outcome >50%

On a composite of events that included mortality, recurrent MI, or hospitalization for heart failure, the rates climbed from 15.7% in the group treated within 24 hours to 23.3% (P < .001) when treatment was delayed. Heart failure, which was not significantly increased when evaluated separately, was not a major contributor to adverse outcomes, but those with delayed treatment did have more recurrent MIs (5.3% vs. 3.7%; P = .02).

Among a long list of differences between groups, those with delayed care had higher rates of atypical chest pain (25.1% vs. 14.8%; P < .001) and dyspnea (32.6% vs. 23.4%; P < .001). Expressed in odds ratios, they were also significantly more likely to be female (OR, 1.23), be aged 75 years or older (OR, 1.44), have diabetes (OR, 1.31), and to arrive at the hospital without aid from emergency medical services (OR, 3.44).

NSTEMI patients with delayed symptom-to-door time were also less likely to have hypertension (54.8% vs. 59.1%; P < .001), chronic kidney disease (20.8% vs. 25.5%), or a family history of cardiovascular disease (4.7% vs. 7.4%; P < .001). They were more likely to have left main and multivessel disease (57.1% vs. 50.5%; P < .001).

The value of early treatment has already been demonstrated for STEMI, which is reflected in guidelines, most of which now emphasize minimizing the door-to-balloon angioplasty time in order to more rapidly restore perfusion, thereby preserving more functional cardiac tissue. This study suggests that benefit from early intervention is also true of NSTEMI.

Reducing prehospital delay in care "should be emphasized as a crucial factor that increases the risk of all-cause mortality in NSTEMI patients," reported the authors, led by Jung-Joon Cha, MD, PhD, division of cardiology, Korea University Anam Hospital, Seoul.

Public Health Campaigns Needed

When asked about the take-home message, Cha, along with the senior author, Tae Hoon Ahn, MD, PhD, contend that delays can be addressed by educating both the public and clinicians.

"We would like to emphasize the need for public health campaigns to make patients more aware of atypical symptoms," Cha said in an interview.

Ahn also believes that there is not enough current emphasis within medical systems to recognize and urgently treat NSTEMI patients with a nontraditional profile.

"Atypical symptoms in NSTEMI patients may lead physicians to underestimate the disease severity," according to Ahn, who participated in an interview on the significance of these results. He said that atypical symptoms should induce clinicians to exercise "more caution rather than to neglect them."

For understanding the value of prompt care in NSTEMI patients, this is important information. However, the importance of the 24-hour threshold as a discriminator of long-term risk was questioned by José A. Barrabés, MD, PhD, head of the acute cardiac care unit, University Hospital Vall d'Hebron, Barcelona.

The cutoff in this study was 24 hours, but Barrabés in an accompanying editorial pointed out that the median delay in those with a symptom-to-door time of at least 24 hours was in fact 72.0 hours.

Intermediate Delay Effect Unknown

"This time lag is unusual and reduces the generalizability of the results," according to Barrabés. He suggested that the exceptional delay increases the likelihood that the characteristics of the patients, such as more comorbidities or lower socioeconomic status, might have played a role in the differences in outcomes.

Asked to elaborate, Barrabés explained that delays in treatment, such as antithrombotic therapy, are plausible explanations for the worse outcomes at 3 years, but it is unclear from this data whether the risk starts at a delay of 24 hours.

"It is certainly plausible that intermediate delays are also associated with a worse prognosis," Barrabés said in an interview, but "the risk associated with an intermediate delay in symptom-to-door time cannot be quantified with the data collected in this study."

Cha and coinvestigators reported no potential conflicts of interest for this study. Barrabés has financial relationship with AstraZeneca, Novo Nordisk, and Rovi.

This article originally appeared on MDedge.com, part of the Medscape Professional Network.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Recommendations